ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP

Please see full Important Safety Information (ISI) below & at https://www.enhertuhcp.com/en/#isi Select ISI Selected Information Regarding Warnings and Precautions ENHERTU is associated with a number of serious, potentially fatal, Warnings and Precautions, including Interstitial Lung Disease/Pneumonitis, Neutropenia, Left Ventricular Dysfunction, Embryo-Fetal Toxicity. Please see Important Safety Information. For complete list of ENHERTU Indications, visit www.enhertuhcp.com. For US HCPs only. ENHERTU® is a Daiichi Sankyo & AstraZeneca brand & is not associated with any individual users. To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.